Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-14

Reasonable question Lupe

We can only assume that the BOD is making progress towards gaining TGA approval for GAD later in the year maybe, but for now

"Clarion Clinics Group, the collaboration between Australia’s foremost clinical experts and IHL (84.5% owned by IHL subsidiary Psychennex Pty Ltd), will provide treatment under the TGA regulated authorised prescriber scheme, for the use of psilocybin for treatment-resistant depression (TRD) and the use of MDMA for PostTraumatic Stress Disorder (PTSD). A number of other depression and anxiety related disorders will be treated with ketamine-assisted psychotherapy"

https://stocknessmonster.com/announcements/ihl.asx-3A617110/

@Lupe it appears that the BOD are going to start with what has already been approved by the TGA
1. Psilocybin for TRD
2. MDMA for PTSD
I assume that once our trial for GAD is finalised then they will seek TGA approval for that indication also.
In the meantime, it's TGA-approved treatments first!

Good luck @Lupe